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Pharmaceutically modified 
subtilisins withstand acidic 
conditions and effectively degrade 
gluten in vivo
Ghassan Darwish1, Eva J. Helmerhorst1, Detlef schuppan2,3, Frank G. oppenheim1 & 
Guoxian Wei1
Detoxification of gluten immunogenic epitopes is a promising strategy for the treatment of celiac 
disease. Our previous studies have shown that these epitopes can be degraded in vitro by subtilisin 
enzymes derived from Rothia mucilaginosa, a natural microbial colonizer of the oral cavity. The 
challenge is that the enzyme is not optimally active under acidic conditions as encountered 
in the stomach. We therefore aimed to protect and maintain subtilisin-A enzyme activity by 
exploring two pharmaceutical modification techniques: PEGylation and Polylactic glycolic acid 
(PLGA) microencapsulation. PEGylation of subtilisin-A (Sub-A) was performed by attaching 
methoxypolyethylene glycol (mPEG, 5 kDa). The PEGylation protected subtilisin-A from autolysis 
at neutral pH. The PEGylated Sub-A (Sub-A-mPEG) was further encapsulated by PLGA. The 
microencapsulated Sub-A-mPEG-PLGA showed significantly increased protection against acid exposure 
in vitro. In vivo, gluten immunogenic epitopes were decreased by 60% in the stomach of mice fed with 
chow containing Sub-A-mPEG-PLGA (0.2 mg Sub-A/g chow) (n = 9) compared to 31.9% in mice fed 
with chow containing unmodified Sub-A (n = 9). These results show that the developed pharmaceutical 
modification can protect Sub-A from auto-digestion as well as from acid inactivation, thus rendering the 
enzyme more effective for applications in vivo.
Gluten proteins are found in wheat, barley and rye, and trigger celiac disease (CeD), a chronic inflammatory 
immune-mediated disease affecting the small intestine1. Immunogenic gluten proteins show unusual resistance 
to degradation by human digestive enzymes2,3. The surviving gluten-derived peptides reach the lamina propria 
in the duodenum where they are deamidated by the enzyme and CeD autoantigen tissue transglutaminase4. 
Immunogenicity is dependent on peptide length, and only peptides longer than 8–11 residues can induce an 
immune response. Therefore, detoxification of gluten can be achieved by their thorough proteolytic fragmenta-
tion. There are a few oral enzymes currently being explored to treat CeD, some of which have reached clinical tri-
als1,5. Two enzymes, prolyl endopeptidase (PEP) from Sphyngomonas capsulata and a glutamine-specific cysteine 
endopeptidase (EP-B2) from barley, together being present in the formulation ALV003 (Alvine Pharmaceuticals), 
have been profoundly investigated for their effect on gluten inactivation3,6–10. A preliminary clinical study showed 
that the effectiveness of PEP from F. meningosepticum is restricted to the length of suitable substrate11, with opti-
mal activity at neutral pH12.
A promising new source of gluten-degrading enzymes are the microbes that colonize the human digestive 
canal, starting in the oral cavity13. Rothia species are part of the commensal oral microflora14 and are gener-
ally considered harmless colonizers associated with oral health, although a few case reports of infections impli-
cating Rothia have been described15. Rothia mucilaginosa as well as Rothia aeria exert a high gluten-degrading 
activity at pH 7.0. Both are capable to thoroughly cleave gluten after glutamine-proline-glutamine (QPQ) and 
leucine-proline-tyrosine (LPY) sequences which are abundant in immunogenic gluten domains16–18. The enzymes 
1Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine 700 Albany Street, Boston, 
Massachusetts, USA. 2Division of Gastroenterology, Beth israel Deaconess Medical center, Harvard Medical School, 
Boston, Massachusetts, USA. 3institute of translational immunology and Research center for immune therapy, 
University Medical Center, Johannes-Gutenberg-University, Mainz, Germany. Correspondence and requests for 
materials should be addressed to G.W. (email: weigx@bu.edu)
Received: 16 August 2018
Accepted: 26 April 2019
Published: xx xx xxxx
opeN
2Scientific RepoRts |          (2019) 9:7505  | https://doi.org/10.1038/s41598-019-43837-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
from Rothia mucilaginosa have been isolated in our laboratory and were identified as subtilisins19. The subtilisin 
enzymes, many being food-grade such as the ones from Bacillus species, could potentially benefit CeD patients if 
they could more effectively abolish gluten immunogenic epitopes during gastro-duodenal transit in vivo19.
Subtilisins are a group of serine proteases, with the Bacillus species showing a MW from 26 to 28 kDa. 
Subtilisin Carlsberg (subtilisin-A or Sub-A, 274 amino acids) is produced by Bacillus licheniformis20 and com-
prises two alpha-helices and a large beta-sheet structure. Given their food-grade status, subtilisins hold promise 
as digestive aides for gluten degradation, but similar to bacterial PEP their activity is dramatically reduced under 
acidic conditions, as prevail in the stomach.
Stability and therapeutic potency of proteins can be improved through the application of pharmaceutical 
modification and/or enteric coating techniques that permit the drug’s release in the target area of interest, e.g., 
the small intestine21,22.
The PEGylation technique consists of covalent and non-covalent attachment of polyethylene glycol (PEG) a 
varying chain length to a molecule such as a therapeutic protein, thereby enhancing its protection from proteo-
lytic degradation and increasing its stability23,24. Usually, PEG is attached to the ɛ-amine group in lysine residues25. 
PEGylated proteins can be further modified by enteric coating techniques, e.g. microencapsulation, to achieve 
further protection in the digestive canal.
PLGA is an FDA approved food-grade polymer. Its features such as being water-insoluble, predictability of 
degradation, ease of fabrication, strength, hydrophobicity, biocompatibility and pliability make PLGA a preferred 
polymeric vehicle for medical applications26–28.
To address the issue of acid sensitivity and autolysis of subtilisin enzymes under acidic conditions, we mod-
ified Sub-A, which showed similar activity as the Rothia subtilisins19 and was readily commericially available, 
with FDA-approved pharmaceutical conjugation (PEGylation) and microencapsulation (emulsion) techniques. 
Activity analysis in vitro and in vivo of the modified enzymes showed a significant protection from inactivation 
by gastric acid, while increasing activity in the small intestine. This led to a significantly improved elimination of 
immunogenic gluten epitopes in vivo. Since this technology is generally applicable, it should be useful not only 
for Sub-A enzymes but also for other glutenases considered for clinical application that are acid sensitive and/or 
prone to autodegradation.
Results
Sub-A undergoes autolysis at neutral pH. When Sub-A (MW 27 kDa) was dissolved at neutral pH, 
a band with a much lower molecular weight (<10 kDa) was observed within 10 min (Fig. 1A). The enzymatic 
activity of subtilisin incubated at 37 °C decreased over time, and this loss of activity must be attributed to autolysis 
(Fig. 1B). The results suggested that Sub-A undergoes autolysis at neutral pH as prevails in the small intestine.
Sub-A is inactive at low pH. Sub-A was highly active in hydrolyzing the Suc-AAPF-pNA substrate at neu-
tral pH (intestinal buffer, pH 7.0) (Fig. 2A). However, the enzyme was inactive at low pH (gastric buffer, pH 
1.5–3.0). Even short-term (10 min) exposure of Sub-A to low pH inactivated the enzyme, since activity could not 
be recovered upon transfer to neutral pH (Fig. 2A). Both autolysis (Fig. 1) and inactivation at low pH are a chal-
lenge for application of gluten degrading enzymes in the digestive tract. Therefore, pharmaceutical modification 
was pursued to render the enzyme more resilient.
PEGylation of Sub-A. Sub-A was modified by PEGylation with mPEG (Sub-A-mPEG). As shown in 
Supplemental Fig. 1 and Supplemental Table 1, the extent of mPEG modification in Sub-A-mPEG was 81.6% 
(~8 of 10 primary amines being PEGylated) as determined by the fluorescamine method (A) and 55.4% (~6 of 
10 primary amines being PEGylated) as determined by the 2,4,6-Trinitrobenzenesulfonic acid (TNBSA) method 
(B). The yield of Sub-A-mPEG, assessed by the weight of the modified product (Sub-A-mPEG)/total weight of the 
agents before modification (Sub-A + mPEG) × 100%) was ~73%, and the PEGylated products contained ~34% 
(w/w) Sub-A (Supplemental Table 2).
PEGylated subtilisin-A (Sub-A-mPEG) activity. PEGylation of Sub-A had a dramatic effect on its autol-
ytic activity (Fig. 3). While Sub-A lost activity over time, the partial modification of the free amines by PEGylation 
virtually completely prevented autolysis. This can be explained by steric hindrance and partial modification of 
the free N-termini in the enzyme structure, which could impede autodegradation by impeding Sub-A domains 
to fold towards the active site. The slightly higher average activity of PEGylated Sub-A compared to unmodified 
Sub-A was not statistically significant.
PLGA encapsulation of Sub-A-mPEG. While autolysis could be effectively prevented with mPEG modifi-
cation, the fact remained that Sub-A mPEG is irreversibly inactivated at low pH, as shown in Fig. 2B. Therefore, to 
obtain an enzyme preparation that could withstand gastroduodenal transit, further pharmaceutical modification 
of Sub-A-mPEG was needed.
To protect Sub-A-mPEG from acidic insults, the enzyme was coated with PLGA. The yield of 
Sub-A-mPEG-PLGA, as determined by the weight of the modified product (Sub-A-mPEG-PLGA)/total weight 
of the agents before modification (Sub-A-mPEG + PLGA) × 100%, was ~43%. The Sub-A concentration in 
Sub-A-mPEG-PLGA was ~8% (w/w) as shown in Supplemental Table 2.
Significant improvements with respect to acid resistance of the enzyme were achieved by PLGA microencap-
sulation. In Fig. 4A, the activity of all compounds, incubated at pH 7.0 and subsequently tested at pH 7.0 are com-
pared. Sub-A processed without the addition of PLGA or mPEG (unmodified control) was active, but the activity 
decreased over time due to autolysis. This autolysis was prevented by mPEG modification, as evidenced by the 
sustained high activity of Sub-A-mPEG over time. PLGA-encapsulated Sub-A-mPEG (Sub-A-mPEG-PLGA) was 
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also active, and retained activity over time. This is expected since after dissolution of the PLGA coating at neutral 
pH the active Sub-A-mPEG enzyme is released.
Next, the effect of PLGA coating on acid resistance was investigated. The compounds were pre-incubated 
in low pH buffer (pH 3.0), and then transferred to a buffer with a neutral pH. The Sub-A controls, as well as 
Sub-A-mPEG were inactive after the acid challenge. However, Sub-A-mPEG-PLGA was fully active after the acid 
Figure 1. Sub-A protein composition and activity. (A) Protein composition of the enzyme dissolved at pH 
1.5, and at pH 7.0, analyzed by SDS-PAGE. Lane 1: MW; Lane 2: Sub-A in pH 1.5; Lane 3: Sub-A in pH 7.0; (B) 
Enzyme activity over time, analyzed using Suc-AAPF-pNA as the enzyme substrate.
Figure 2. Activity of Sub-A and PEGylated Sub-A (Sub-A-mPEG). The activity was analyzed at pH 7.0 and at 
pH 3.0, n = 3. (A) Sub-A; (B) Sub-A-mPEG.
4Scientific RepoRts |          (2019) 9:7505  | https://doi.org/10.1038/s41598-019-43837-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
challenge (Fig. 4B). These results indicate that the PLGA coating had protected the encapsulated Sub-A-mPEG 
enzyme from denaturation during the acid exposure.
Gliadin hydrolysis by Sub-A-mPEG-PLGA. To assess the activity of Sub-A and Sub-A-mPEG-PLGA 
towards a gluten substrate, both enzyme preparations were exposed to acidic conditions at 37 °C for 0, 3 and 24 hr, 
and then incubated with mixed gliadins (the major fraction of gluten proteins) at neutral pH and at 37 °C for 0 or 
1 hr. Gliadin degradation was monitored by SDS-PAGE. Figure 5A shows the results obtained with Sub-A, and 
Fig. 5B the results obtained with Sub-A-mPEG-PLGA. After acid exposure, Sub-A was inactive, as evidenced 
by the fact that gliadins remained intact after mixing with the enzyme. However, Sub-A-mPEG-PLGA induced 
gliadin degradation after acid exposure for 24 hr, which indicates the enzyme remained active even long after acid 
challenge (Fig. 5B, lane 3, 5 and 7). These results confirm that Sub-A-mPEG-PLGA can withstand acid challenge 
and that its Sub-A-mPEG component can efficiently degrade gliadins once released, without significant autolytic 
degradation.
Detoxification of gliadin immunogenic epitopes in vivo. To experimentally explore if Sub-A-mPEG- 
PLGA would be able to degrade and abolish immunogenic gliadin epitopes during gastro-intestinal transit, an in 
vivo experiment was carried out. Three groups of 9 mice each were fasted for 18 hr, and received either gluten con-
taining chow alone, gluten-chow supplemented with Sub-A or with Sub-A-mPEG-PLGA. The mice ingested ~1 g 
chow in 1 hr. After digestion for two more hours, the stomach contents of the mice were harvested, gliadin pep-
tides extracted and quantified for the R5 epitope, which represents a highly immunogenic gliadin peptide domain 
that is present in many gliadin molecules using The R5-ELISA. As shown in Fig. 6, gluten immunogenic epitopes 
in the stomach of the mice fed gluten-chow and non-modified Sub-A were reduced by 31.9%. Notably, the 
reduction of R5-epitopes was significantly higher 60.0%, (p < 0.01) in mice fed with gluten-chow supplemented 
with Sub-A-mPEG-PLGA. This showed that the efficacy of gliadin degradation in vivo was doubled after enzyme 
Figure 3. PEGylation protects Sub-A from autolysis. The activity of Sub-A and Sub-A-mPEG was monitored 
over time at pH 7.0, n = 3.
Figure 4. mPEG-PLGA modification renders Sub-A resistant to acid exposure. (A) Enzyme preparations pre-
incubated at pH 7.0 and tested at pH 7.0; (B) Enzyme preparations pre-incubated at pH 3.0 and tested at pH 7.0, 
n = 3.
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modification with mPEG and encapsulation by PLGA. Overall, Sub-A in this twofold modified form more effi-
ciently removes immunogenic epitopes from the gastric lumen, which may facilitate to digest epitopes in the 
pH-neutral duodenal region.
Discussion
Protein-based drugs hold promise as therapeutic agents because of their high specificity, but they often display 
short half-life’s in vivo, either due to rapid excretion or proteolysis. Instability and autodegradation of enzymes 
are major challenges for their therapeutic application. PEG modification usually improves protein stability29 and 
encapsulation of chymotrypsin in PLGA microspheres prevented loss of its enzymatic activity29. Here we com-
bined PEGylation and PLGA microencapsulation to protect the gluten degrading enzyme subtilisin-A from inac-
tivation due to acid exposure as well as autolysis at neutral pH.
Subtilisins have a potential to be used for therapeutic application in the treatment of CeD due to their 
gluten-degrading activity and their food grade availability. However, subtilisin-A, like many other enzymes, is 
only weakly active under acidic conditions30. Sub-A activity was lost at low pH, and could not be recovered after 
transfer to neutral pH, suggesting that the enzyme’s active site is denatured at low pH. PLGA microencapsulation 
efficiently stabilized the enzyme under acidic conditions.
PEGylation successfully protected Sub-A autolytic degradation, while retaining its ability to digest externally 
added substrates. The size of mPEG has been reported as a factor to impact the efficiency of PEG modification. 
mPEG with molecular weights ~5 kDa have been found to be most efficient for protecting enzyme proteins29,31,32. 
Larger MW (>10 kDa) PEG molecules tend to fold and occupy a large surface area of the protein, interfering with 
substrate binding ability33,34. Our modification using 5 kDa mPEG yielded a high conjugation efficiency (~55%), 
which is comparable to studies with other protein substrates in which the PEG modification efficiency ranged 
between 50–60%32,35.
We investigated the extent of mPEG modification by the fluorescamine and the TNBSA assays31. TNBSA 
recognizes the primary amines in unfolded proteins, compared to the fluorescamine that detects amines in folded 
proteins. Sub-A has 10 primary amines including 9 Lysine (K) residues and one free N-terminus36. We showed 
that 8 vs 6 of the 10 primary amines in Sub-A were occupied as determined by fluorescamine vs TNBSA in line 
with 2 internal amines that are inaccessible in the native stet of the enzyme and 6 PEGylated primary amines. 
Importantly, PEGylation of these 6 amines did not compromise enzymatic activity of Sub-A, as shown in Fig. 4. 
~60% PEGylation has been demonstrated previously to induce no significant changes in secondary and tertiary 
structure of the enzyme32, retaining 87% activity37. It is possible that a lower degree of PEGylation may improve 
enzyme activity, while not dramatically compromising its stability, but such optimization will require further 
studies.
Our in vitro and in vivo studies clearly demonstrate that PLGA microencapsulation (Sub-A-mPEG-PLGA) 
dramatically protected the enzyme against acid denaturation. The mechanisms of drug release from PLGA coat-
ings include a collective PLGA degradation process of bulk or surface diffusion and erosion neutral vs acidic 
Figure 5. Sub-A-mPEG-PLGA after acid challenge can degrade gliadins. Sub-A (A) or Sub-A-mPEG-PLGA 
(B) were incubated at 37 °C in acidic conditions (pH 3.0) for 0, 3, or 24 hr, and then transferred to pH 7.0. 
Enzyme activity was monitored at t = 0 h and t = 1 h using mixed gliadins as the substrate. Lane 1: MW; Lane 2, 
4, 6: Sub-A or Sub-A-mPEG-PLGA in pH 3.0 for 0, 3, 24 hr, then gliadin added and incubated for 0 hr; Lane 3, 5, 
7: Sub-A or Sub-A-mPEG-PLGA in pH 3.0 for 0, 3, 24 hr, then gliadin added and incubated for 1 hr.
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pH38,39. In addition, PLGA degradation depends on many factors such as molecular weight of the polymer, the 
degree of crystallinity, the glass-transition temperature of the polymer, and the size and shape of the matrix40.
The enzyme type, load, and conjugation also impact the release rate and pattern of the coated enzyme from 
PLGA40. The presence of the PEG polymer conjugated with the enzyme likely affects the release profile of Sub-A. 
Since there are many variables that influence the degradation process, the release rate and patterns are often 
unpredictable, especially in vivo where the pH conditions can fluctuate in time, depending on the ingested food 
and depending on the anatomical location.
The animal experiment confirmed the in vitro finding, where the encapsulated enzyme was better protected 
than subtilisin-A and twice as efficient in degrading gliadins. Activity was only measured in the stomach contents. 
It can be envisions but needs to be shown that activities would even be higher in the neutral duodenal environ-
ment, where PLGA dissolution and enzyme release are be favored.
Overall, the combination of mPEG and PLGA coating of subtilisins provides a novel strategy to deliver oth-
erwise acid-sensitive gluten-degrading enzymes to the gastrointestinal tract with enhanced activity and stability. 
To our knowledge, this is the first study to demonstrate a synergistic effect of PEGylation and PLGA encapsula-
tion for enteric coating to preserve the activity as well as stability of food grade subtilisins. The combination of 
PEGylation and microencapsulation could be used to modify other gluten-degrading enzymes, including, e.g., 
prolyl endopeptidases, and serve as a general tool for a more efficient glutenase therapy of celiac disease.
Materials and Methods
Modification of Sub-A. Sub-A from B. licheniformis (Sigma, product number 5380) was modified by 
PEGylation and microencapsulation as schematically representated in Fig. 7.
PEGylation of Sub-A. PEGylation of Sub-A was performed using the method reported by Castellanos41 and 
Mabrouk42. Briefly, Sub-A (40 mg) and activated mPEG (120 mg, 5 kDa) were dissolved in 20 ml of 0.1 M sodium 
borate buffer (pH 9.2) at an approximate molar ratio of 1:3 (solvent-accessible lysine residues in Sub-A to mPEG) 
and stirred for 3 hr at 4 °C. The reaction was quenched by the addition of 20 ml of 0.1 M potassium phosphate 
Figure 6. Sub-A-mPEG-PLGA is active in vivo. Three groups of mice were treated either with gluten-
containing chow only (n = 9), chow supplemented with Sub-A (n = 9) or chow supplemented with Sub-A-
mPEG-PLGA. After 3 hr, mice were euthanized, stomach contents harvested, and the survival of the R5 epitopes 
was determined via ELISA. (A) Box plot showing the individual data points; (B) Average +/− SE. Data were 
analyzed with SPSS. ***p < 0.001.
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buffer (pH 7.0). Non-reacted mPEG and buffer salts were removed by dialysis using membranes with a cut-off of 
8 kDa (Spectra Medical Industries, Laguna Hills, CA) against 1 L of miliQ water for 24 hr. The PEGylated Sub-A 
(Sub-A-mPEG conjugates) in aqueous solution was frozen in −80 °C for 30 min and lyophilized (Virtis FM 25 
EL, NY, USA) at a condenser temperature of −70 °C and a pressure of <20 millitorr. Lyophilized protein powders 
were kept at −20 °C until used in the experiments.
Validating PEGylation efficiency. The PEGylation efficiency of Sub-A was evaluated with the fluores-
camine method for folded proteins31,43,44 and the TNBSA methods for unfolded proteins31.
Fluorescamine Assay. The average number of free amino groups in the PEGylated Sub-A surface was determined 
by a fluorescamine method31,43,44. Fluorescamine, a heterocyclic dione, reacts with primary amines to form a 
fluorescent product. The fluorescence of a solution containing protein plus fluorescamine is proportional to the 
quantity of free amine groups present. Unmodified and mPEG-modified Sub-A were dissolved in PBS (pH 7.4) 
at 0, 0.1, 0.2 and 0.3 mg/ml, and aliquots (150 μL) was pipetted into each well of a 96-black-well microplate (flat 
bottom) in triplicate. The fluorescence was measured immediately after mixing with 50 μL of 0.3 mg/mL fluo-
rescamine solution (in acetone) at an excitation wavelength of 360 nm, and an emission wavelength of 465 nm. 
Fluorescence intensity values were plotted versus the Sub-A concentrations. The percentage of mPEG modifica-
tion was calculated using the formula [1 − (slope of Sub-A-mPEG/Sub-A)] × 100.
TNBSA Assay. Since fluorescamine cannot react with unexposed primary amines of folded proteins, the TNBSA 
(2,4,6-Trinitrobenzenesulfonic acid) method45 was used to further estimate the extent of mPEG modification. The 
protein is unfolded in HCl and SDS, rendering all amino groups solvent accessible. The assay was performed as 
follows: Sub-A-mPEG and Sub-A were dissolved in 1 ml of 0.2 M sodium bicarbonate buffer (pH 8.5) to achieve 
concentrations between 0.1 and 0.4 mg/ml. To these solutions and buffer blanks, 0.25 ml of 0.01% TNBSA (w/v), 
0.25 ml of 10% SDS solution (w/v), and 0.125 ml of 1 N HCl were added. The mixtures were incubated at 37 °C 
for 2 hr, and their absorbance at 335 nm was subsequently determined (Genios microtiter plate reader, Tecan, 
Männedorf, Switzerland). The absorbance values were calibrated by subtracting the values of buffer blanks and 
were then plotted versus the Sub-A/Sub-A-mPEG concentration. The percentage of mPEG modification was 
calculated using the formula [1 − (slope of Sub-A-mPEG/Sub-A)] × 100.
Microencapsulation of PEGylated Sub-A. Microencapsulation of PEGylated Sub-A was performed 
essentially as described29. Sub-A-mPEG (10 mg) was dissolved in 0.5 ml of 0.2 M sodium bicarbonate buffer 
(NaHCO3, pH 10.0), and poly-lactic glycolic acid (PLGA) (90 mg) was dissolved in 0.5 ml acetone. The two solu-
tions were mixed, vortexed, followed by addition of 3 ml of light liquid paraffin and 0.05 ml of Span 80 while with 
vortexing. The mixture was placed in 40 ml beaker while stirring at 500–700 rpm using for 3 hr at room tempera-
ture until the acetone evaporated completely, resulting in the formation of microcapsules. The formed microcap-
sules were harvested by centrifugation (2 min, 7,000 rpm), washed (5x) in petroleum ether (40–60° grade), and 
dried at room temperature for 24 hr.
Acid challenge test. To test the stability and activity of Sub-A and Sub-A-mPEG after incubation under 
acidic conditions, the enzymes were dissolved in diluted gastric buffer (pH 3.0, Sigma 01651) at a concentration 
of 0.25 mg/ml. After incubation at 37 °C for 1 hr, the solutions were neutralized and diluted by adding an intestinal 
buffer (pH 7.0, Sigma 53757). The enzymes (0.25 µg/ml) were then tested for activity using Suc-AAPF-pNA as 
the substrate.
Figure 7. Schematic representation of the pharmaceutical coating procedure applied to Sub-A. [Radi et al., 
Med. Chem. Commun. 2016, 7, 1738–1744] - Reproduced by permission of The Royal Society of Chemistry. All 
rights reserved.
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Enzyme activity assessment using p-nitroanilide-derivatized peptide. The aliquots (50 µl) of 
Sub-A, Sub-A-mPEG, or Sub-A-mPEG-PLGA were added to 150 µl of PBS (pH 7.0) and diluted to 0.25 µg/ml. 
The 200 µl aliquots were added in triplicate to a 96-well microtiter plate (Costar 3596, Corning, NY, USA) mixed 
with 0.2 mM n-succinyl-ala-ala-pro-phe-p-nitroanilide (Suc-AAPF-pNA, Sigma). Substrate hydrolysis was spec-
trophotometrically monitored at 405 nm, at 37 °C for 1 hr at 10 min intervals using a Genios microtiter plate 
reader (Tecan, Männedorf, Switzerland).
Enzyme activity assessment using gliadins. Sub-A and Sub-A-mPEG-PLGA were dissolved in diluted 
HCl buffer (pH 3.0) to 1 mg/ml and incubated at 37 °C for 0, 3 and 24 hr. The 24 hr time point was chosen to 
capture any low enzyme activity that might be present in the sample. Gliadin (Sigma) hydrolysis activity of each 
pre-treated enzyme sample were determined by incubating a 40 fold dilution of the pretreated enzyme (25 µg/ml) 
samples with gliadin (250 µg/ml) in PBS (pH 7.0) at 37 °C. Gliadin degradation was monitored after 0 and 1 hr of 
incubation in 100 µl sample aliquots subjected to 4–12% SDS PAGE.
Assessment of enzyme activity in vivo. All animal experiments were conducted using institutionally 
approved protocols by Boston University’s Institutional Animal Care and Use Committee (IACUC) and Animal 
Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. The animals were housed in a controlled envi-
ronment (22 °C, 12 hr day/night cycle) with ad libitum food and drink access. For the in vivo experiment, 1 g of 
powdered mouse chow (2018, Envigo, Cambridgeshire, UK), containing 18% crude proteins where ~50 mg gluten 
or ~25 mg gliadin/g chow included, was added into a 2 ml Eppendorf tube and mixed incrementally with 400 to 
600 µl sterilized water by packing layer by layer to form a pellet, where a 200 µl-yellow pipette tip was inserted 
to cast a hollow center for loading of the enzyme samples (Fig. 8). The chow pellets were dried in the SpeedVac 
machine (SpeedVac plus SC110 A, Savant, NY, USA) for 3 hr. Sub-A or Sub-A-mPEG-PLGA were added in an 
amount of 0.2 mg to the center of the pellets, which were then closed with the mice chow paste.
Balb/c female mice (9 weeks old, n = 30) were acclimatized for a week. After 18 hr of fasting, the mice were 
fed for 3 hr as follows: Group I (n = 9): chow pellets without added enzyme; Group II (n = 9): chow pellets with 
Sub-A; and Group III (n = 9): chow pellets with Sub-A-mPEG-PGLA; and no food controls (n = 3). The mice 
were then euthanized, and stomach contents were collected and suspended in 2 ml of sterile water, and boiled 
(100 °C, 10 min), and then centrifuged (2,000 g, 2 min, at 4 °C). The suspensions were collected then mixed with 
60% ethanol to extract gliadin peptides. After shaking (40 rpm) at room temperature for 1 hr, the mixtures were 
centrifuged (2,000 g × 10 min, 4 °C), and the ethanol extracted sample supernatants were collected. The protein 
content of the supernatants were determined by using the BCA protein assay kit (Sigma).
The concentration of immunogenic gluten epitopes of the extracted samples were subsequently analyzed 
using the ELISA-R5 assay kit (RIDASCREEN Gliadin, R-Biopharm, Darmstadt, Germany). This test measures 
the QQPFP, QQQFP and LQPFP epitopes sequence that occurs as important T cell stimulatory peptide epitope 
in several gliadin molecules17. The antibody coated microtiter plate wells were blocked with 1% defatted milk 
powder in PBS (200 µl). After incubation at room temperature for 1 hr, the plate was washed for three times with 
PBST (PBS + 0.5% Tween-20). The protein concentration of the stomach samples were adjusted to 160 µg/ml, and 
diluted 3,200-fold in dilution buffer. This dilution factor was determined to reduce gliadin levels to concentrations 
falling within the linear part of the standard curve. Aliquots of 100 µl of each of the diluted samples, as well as the 
Figure 8. Method for the preparation of mouse chow with added enzyme (Sub-A or Sub-A-mPEG).
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controls of 0 ppb and 80 ppb gliadin standard solutions included in the kit, were added to each well, followed the 
instructions provided by the manufacturer.
Statistics. Data were analysed using SPSS 17.0 software and were computed with GraphPad Prism 8. Standard 
one way ANOVA (non-parametric, when samples failed normality or equality of variance statistical tests) were 
used to test for statistical significance between groups. The data were represented as average ± standard error of 
mean (SEM). A value of p < 0.05 was considered to be statistically significant.
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